Our results demonstrate SLC38A9 is involved in AD-related pathology and its cognitive impairment, and may offer new therapeutic targets to AD.
Chen et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: